FDA Seeks Public Input on Health Equity for Medical Devices

In an effort to promote equitable health outcomes across diverse populations in the U.S., the U.S. Food and Drug Administration (FDA) has released a Discussion Paper focusing on how medical device development can advance health equity. The paper, titled "Health Equity for Medical Devices," was published by the FDA's Center for Devices and Radiological Health (CDRH) in early August.

The paper highlights key considerations for device manufacturers when conducting clinical studies aimed at supporting the development of innovative medical devices. It identifies three critical factors: disease burden or condition, physiology, anatomy, and pathophysiology, and technology. These aspects are important for ensuring that clinical trials accurately represent the populations that the devices are intended to serve.

Additionally, the paper discusses the importance of evaluating whether data derived from clinical studies is truly reflective of the intended use population for each device.

The FDA is encouraging public comment on the points raised in the Discussion Paper, as well as on other related factors to ensure health equity in medical device development. Comments can be submitted via the Regulations.gov website (reference docket number FDA-2024-N-3816) until October 4, 2024. The paper is available for download on the FDA website.